Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases

Huifeng Yun; Fenglong Xie; John W Baddley; Kevin Winthrop; Kenneth G Saag; Jeffrey R Curtis

doi:10.3899/jrheum.160685

Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases

J Rheumatol. 2017 Jul;44(7):1083-1087. doi: 10.3899/jrheum.160685. Epub 2017 Mar 15.

Authors

Huifeng Yun^{1

2}, Fenglong Xie^{1

2}, John W Baddley^{1

2}, Kevin Winthrop^{1

2}, Kenneth G Saag^{1

2}, Jeffrey R Curtis^{3

4}

Affiliations

¹ From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA.
² H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham.
³ From the University of Alabama at Birmingham, Birmingham, Alabama; Oregon Health and Science University, Portland, Oregon, USA. jcurtis@uab.edu.
⁴ H. Yun, PhD, University of Alabama at Birmingham; F. Xie, MS, University of Alabama at Birmingham; J.W. Baddley, MD, MPH, University of Alabama at Birmingham; K. Winthrop, MD, MPH, Oregon Health and Science University; K.G. Saag, MD, MSc, University of Alabama at Birmingham; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham. jcurtis@uab.edu.

Abstract

Objective: The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases.

Methods: Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression.

Results: Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years.

Conclusion: HZ vaccination was significantly protective only for about 5 years among patients with AI.

Keywords: AUTOIMMUNE DISEASES; HERPES ZOSTER; INFECTION; VACCINATION.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Autoimmune Diseases*
Female
Herpes Zoster / epidemiology
Herpes Zoster / prevention & control*
Herpes Zoster Vaccine*
Humans
Incidence
Inflammation*
Male
Medicare
Retrospective Studies
Treatment Outcome
United States
Vaccination

Substances

Herpes Zoster Vaccine

Grants and funding

UM1 AR065705/AR/NIAMS NIH HHS/United States